Adrien Lemoine

Adrien brings 20 years of experience in pharma and biotech to Bloomsbury Genetic Therapies. Following roles of increasing responsibility in commercial analysis, strategy, operations, business & corporate development at GSK and AstraZeneca, Adrien’s latest appointment was Chief Business Officer of Orchard Therapeutics, in charge of business development & program management. He played a leading part in the Orchard’s fundraising efforts (Series B, Series C, NASDAQ IPO and follow-on financing) which raised over $750M as well as led a $75 million debt facility. Adrien holds an Engineering Degree from CentraleSupélec (Paris, France) and a MSc in Engineering and Physical Science in Medicine from Imperial College (London, UK).